Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

SCI Pharmtech Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

SCI Pharmtech şirketinin toplam hissedar öz sermayesi NT$5.1B ve toplam borcu NT$1.1B olup, bu da borç-öz sermaye oranını 22.3% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla NT$6.8B ve NT$1.8B dir. SCI Pharmtech 'in FAVÖK'ü NT$145.3M faiz karşılama oranı -43.2 dur. Şirketin NT$911.5M tutarında nakit ve kısa vadeli yatırımları bulunmaktadır.

Anahtar bilgiler

22.3%

Borç/özkaynak oranı

NT$1.12b

Borç

Faiz karşılama oranı	-43.2x
Nakit	NT$911.46m
Eşitlik	NT$5.05b
Toplam yükümlülükler	NT$1.78b
Toplam varlıklar	NT$6.83b

Son finansal sağlık güncellemeleri

Güncelleme yok

Recent updates

We Think That There Are More Issues For SCI Pharmtech (TWSE:4119) Than Just Sluggish Earnings

Mar 27

Analysts Just Shipped A Captivating Upgrade To Their SCI Pharmtech, Inc. (TPE:4119) Estimates

Apr 07

There May Be Reason For Hope In SCI Pharmtech's (TPE:4119) Disappointing Earnings

Mar 30

SCI Pharmtech, Inc. (TPE:4119) Is Yielding 6.3% - But Is It A Buy?

Mar 08

SCI Pharmtech (TPE:4119) Shareholders Booked A 54% Gain In The Last Three Years

Jan 25

Some SCI Pharmtech, Inc. (TPE:4119) Analysts Just Made A Major Cut To Next Year's Estimates

Dec 30

Declining Stock and Solid Fundamentals: Is The Market Wrong About SCI Pharmtech, Inc. (TPE:4119)?

Dec 29

Would SCI Pharmtech, Inc. (TPE:4119) Be Valuable To Income Investors?

Dec 08

A Look At The Intrinsic Value Of SCI Pharmtech, Inc. (TPE:4119)

Nov 17

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: 4119 'nin kısa vadeli varlıkları ( NT$2.0B ) kısa vadeli yükümlülüklerini ( NT$778.3M ) aşıyor.

Uzun Vadeli Yükümlülükler: 4119 şirketinin kısa vadeli varlıkları ( NT$2.0B ) uzun vadeli yükümlülüklerini ( NT$1.0B ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: 4119 'nin net borç/öz sermaye oranı ( 4.2% ) tatmin edici olarak değerlendirilmektedir.

Borcun Azaltılması: 4119 şirketinin borç/öz sermaye oranı son 5 yılda 0% seviyesinden 22.3% seviyesine yükseldi.

Borç Kapsamı: 4119 'nin borcu işletme nakit akışı ( 9.4% ) tarafından iyi bir şekilde karşılanmıyor.

Faiz Kapsamı: 4119 ödediğinden daha fazla faiz kazandırıyor, dolayısıyla faiz ödemelerinin karşılanması bir sorun teşkil etmiyor.

SCI Pharmtech Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Recent updates

New minor risk - Profit margin trend

Second quarter 2024 earnings released: EPS: NT$0.52 (vs NT$1.86 in 2Q 2023)

SCI Pharmtech, Inc. to Report Q2, 2024 Results on Aug 09, 2024

Upcoming dividend of NT$1.25 per share

First quarter 2024 earnings released: EPS: NT$0.37 (vs NT$0.59 in 1Q 2023)

SCI Pharmtech, Inc. Announces Board Changes

SCI Pharmtech, Inc. to Report Q1, 2024 Results on May 09, 2024

SCI Pharmtech, Inc. to Report Q1, 2024 Results on May 09, 2024

We Think That There Are More Issues For SCI Pharmtech (TWSE:4119) Than Just Sluggish Earnings

Full year 2023 earnings released: EPS: NT$2.70 (vs NT$2.88 in FY 2022)

SCI Pharmtech, Inc., Annual General Meeting, May 30, 2024

Third quarter 2023 earnings released: EPS: NT$0.33 (vs NT$0.45 in 3Q 2022)

New minor risk - Shareholder dilution

SCI Pharmtech, Inc. announced that it expects to receive TWD 120 million in funding

Second quarter 2023 earnings released: EPS: NT$1.86 (vs NT$1.31 in 2Q 2022)

Upcoming dividend of NT$0.25 per share at 0.2% yield

SCI Pharmtech, Inc. Announces Cash Dividend, Payable on September 1, 2023

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Price target increased by 24% to NT$104

Less than half of directors are independent

Now 21% undervalued

Consensus revenue estimates fall by 25%

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

SCI Pharmtech, Inc. Announces Appointment of General Manager of the Board of Directors

First quarter 2022 earnings: EPS exceeds analyst expectations

Price target increased to NT$84.00

Less than half of directors are independent

Third quarter 2021 earnings released: EPS NT$0.31 (vs NT$1.98 in 3Q 2020)

Upcoming dividend of NT$0.50 per share

Second quarter 2021 earnings released: EPS NT$0.05 (vs NT$3.04 in 2Q 2020)

First quarter 2021 earnings released: EPS NT$0.52 (vs NT$2.62 in 1Q 2020)

Analysts Just Shipped A Captivating Upgrade To Their SCI Pharmtech, Inc. (TPE:4119) Estimates

Consensus revenue estimates increase to NT$742.0m

There May Be Reason For Hope In SCI Pharmtech's (TPE:4119) Disappointing Earnings

Full year 2020 earnings released: EPS NT$4.53 (vs NT$7.19 in FY 2019)

SCI Pharmtech, Inc. (TPE:4119) Is Yielding 6.3% - But Is It A Buy?

SCI Pharmtech (TPE:4119) Shareholders Booked A 54% Gain In The Last Three Years

Investor sentiment improved over the past week

Some SCI Pharmtech, Inc. (TPE:4119) Analysts Just Made A Major Cut To Next Year's Estimates

Analysts update estimates

Declining Stock and Solid Fundamentals: Is The Market Wrong About SCI Pharmtech, Inc. (TPE:4119)?

Price target lowered to NT$109

Investor sentiment deteriorated over the past week

New 90-day low: NT$112

Would SCI Pharmtech, Inc. (TPE:4119) Be Valuable To Income Investors?

A Look At The Intrinsic Value Of SCI Pharmtech, Inc. (TPE:4119)

Third quarter 2020 earnings released: EPS NT$2.38

Revenue beats expectations, earnings disappoint

Third quarter 2020 earnings released: EPS NT$2.38

Revenue beats expectations, earnings disappoint

First half earnings released

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Sağlıklı şirketleri keşfedin